Table 5.

Risk for incidental OHE in patients with baseline CHE according to testing strategy.

Single-test strategy
	PHES HR (95%CI)	p	ICT HR (95%CI)	p	StE HR (95%CI)	p
CHE	1.79 (1.02, 3.13)	0.04	1.54 (0.90, 2.63)	0.11	1.69 (1.01–3.07)	0.04
Prior OHE	2.06 (1.17, 3.63)	0.01	2.11 (1.18, 3.75)	0.01	2.04 (1.16, 3.60)	0.01
MELD	1.03 (0.99, 1.08)	0.05	1.05 (1.01, 1.09)	0.01	1.04 (1.00, 1.08)	0.14
Two-test strategy
	PHES + ICT HR (95%CI)	p	PHES + StE HR (95%CI)	p	ICT + StE HR (95%CI)	p
CHE	2.02 (1.13, 3.59)	0.01	1.72 (1.02, 3.03)	0.04	1.48 (0.85, 2.59)	0.16
Prior OHE	2.07 (1.16, 3.69)	0.01	2.04 (1.16, 3.61)	0.01	2.11 (1.18, 3.76)	0.01
MELD	1.04 (1.00, 1.08)	0.05	1.03 (0.99, 1.08)	0.15	1.05 (1.01, 1.09)	0.01

CHE: covert hepatic encephalopathy, HR (95%CI): hazards ratio and confidence interval, ICT: inhibitory control test, MELD: model for end-stage liver disease, OHE: overt hepatic encephalopathy, PHES: psychometric hepatic encephalopathy score, StE: Stroop EncephalApp